@article{194a9995d11a4a1bbec50e1bf20b0bc7,
title = "Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting",
abstract = "Introduction: The Prostate Cancer Foundation (PCF) convened a PCF prostate-specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 November 2019, at Weill Cornell Medicine, New York, NY. Methods: The meeting was attended by 22 basic, translational, and clinical researchers from around the globe, with expertise in PSMA biology, development and use of PSMA theranostics agents, and clinical trials. The goal of this meeting was to discuss the current state of knowledge, the most important biological and clinical questions, and critical next steps for the clinical development of PSMA positron emission tomography (PET) imaging agents and PSMA-targeted radionuclide agents for patients with prostate cancer. Results: Several major topic areas were discussed including the biology of PSMA, the role of PSMA-targeted PET imaging in prostate cancer, the physics and performance of different PSMA-targeted PET imaging agents, the current state of clinical development of PSMA-targeted radionuclide therapy (RNT) agents, the role of dosimetry in PSMA RNT treatment planning, barriers and challenges in PSMA RNT clinical development, optimization of patient selection for PSMA RNT trials, and promising combination treatment approaches with PSMA RNT. Discussion: This article summarizes the presentations from the meeting for the purpose of globally disseminating this knowledge to advance the use of PSMA-targeted theranostic agents for imaging and treatment of patients with prostate cancer.",
keywords = "PET imaging, clinical trials, medical oncology, nuclear medicine, prostate-specific membrane antigen (PSMA), radiation therapy, radiology, radionuclides, radiopharmaceuticals, urology",
author = "Miyahira, {Andrea K.} and Pienta, {Kenneth J.} and Babich, {John W.} and Bander, {Neil H.} and Jeremie Calais and Peter Choyke and Hofman, {Michael S.} and Larson, {Steven M.} and Lin, {Frank I.} and Morris, {Michael J.} and Pomper, {Martin G.} and Shahneen Sandhu and Scher, {Howard I.} and Tagawa, {Scott T.} and Scott Williams and Soule, {Howard R.}",
note = "Funding Information: SML was named as one of the inventors in the following patent applications relating to GPA33: SK2014‐074, SK2015‐091, SK2017‐079, SK2018‐045, SK2014‐116, SK2016‐052, and SK2018‐068 filed by MSK. SML reports receiving commercial research grants from YMABS Therapeutics Inc, Genentech, Inc, WILEX AG, Telix Pharmaceuticals Limited, and Regeneron Pharmaceuticals, Inc; holding ownership interest/equity in Elucida Oncology, Inc, and holding stock in YMABS Therapeutics Inc, ImaginAb, Inc. SML is the inventor and owner of issued patents both currently unlicensed and licensed by MSK to Samus Therapeutics, Inc, Elucida Oncology, Inc, and YMABS Therapeutics, Inc. SML serves or has served as a consultant to Cynvec LLC, Eli Lilly & Co, Prescient Therapeutics Limited, Advanced Innovative Partners, LLC, Gerson Lehrman Group, Progenics Pharmaceuticals, Inc, and Janssen Pharmaceuticals, Inc. Funding Information: MGP is supported by CA134675, CA184228, and CA13467. Funding Information: We thank Bayer for the generous unrestricted support of this meeting. We also acknowledge the meeting planning efforts of Carla Appling (PCF) and Cynthia Guzman (Weill Cornell Medicine). MSH is supported by a clinical fellowship award from the Peter MacCallum Foundation. He receives additional grant support from the PCF, Movember, Australian Government (Medical Research Future Fund), PCF of Australia, Victorian Cancer Agency, and the US Department of Defense. MGP is supported by CA134675, CA184228, and CA13467. STT is supported by the PCF, Department of Defense, and National Institutes of Health. Funding Information: MSH is supported by a clinical fellowship award from the Peter MacCallum Foundation. He receives additional grant support from the PCF, Movember, Australian Government (Medical Research Future Fund), PCF of Australia, Victorian Cancer Agency, and the US Department of Defense. Funding Information: STT is supported by the PCF, Department of Defense, and National Institutes of Health. Funding Information: KJP receives research funding from Progenics, Inc. Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",
year = "2020",
month = nov,
day = "1",
doi = "10.1002/pros.24056",
language = "English (US)",
volume = "80",
pages = "1273--1296",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "15",
}